Importance of Mesoporous Silica Particle Size in the Stabilization of Amorphous Pharmaceuticals-The Case of Simvastatin

Zobrazit minimální záznam

dc.contributor.author Knapik-Kowalczuk, Justyna cze
dc.contributor.author Kramarczyk, Daniel cze
dc.contributor.author Chmiel, Krzysztof cze
dc.contributor.author Romanová, Jana cze
dc.contributor.author Kawakami, Kohsaku cze
dc.contributor.author Paluch, Marian cze
dc.date.accessioned 2021-05-15T18:21:01Z
dc.date.available 2021-05-15T18:21:01Z
dc.date.issued 2020 eng
dc.identifier.issn 1999-4923 eng
dc.identifier.uri https://hdl.handle.net/10195/77079
dc.description.abstract In this paper, the role of mesoporous silica (MS) particle size in the stabilization of amorphous simvastatin (SVT) is revealed. For inhibiting recrystallization of the supercooled drug, the two MS materials (Syloid((R)) XDP 3050 and Syloid((R)) 244 FP) were employed. The crystallization tendency of SVT alone and in mixture with the MS materials was investigated by Differential Scanning Calorimetry (DSC) and Broadband Dielectric Spectroscopy (BDS). Neither confinement of the SVT molecules inside the MS pores nor molecular interactions between functional groups of the SVT molecules and the surface of the stabilizing excipient could explain the observed stabilization effect. The stabilization effect might be correlated with diffusion length of the SVT molecules in the MS materials that depended on the particle size. Moreover, MS materials possessing different particle sizes could offer free spaces with different sizes, which might influence crystal growth of SVT. All of these factors must be considered when mesoporous materials are used for stabilizing pharmaceutical glasses. eng
dc.format "384-1"-"384-21" eng
dc.language.iso eng eng
dc.publisher MDPI eng
dc.relation.ispartof Pharmaceutics, volume 12, issue: 4 eng
dc.rights open access (CC BY 4.0) eng
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject simvastatin eng
dc.subject amorphous pharmaceuticals eng
dc.subject mesoporous silica eng
dc.subject stabilization eng
dc.subject recrystallization eng
dc.subject simvastatin cze
dc.subject amorfní léčiva cze
dc.subject mezoporézní silika cze
dc.subject stabilizace cze
dc.subject rekrystalizace cze
dc.title Importance of Mesoporous Silica Particle Size in the Stabilization of Amorphous Pharmaceuticals-The Case of Simvastatin eng
dc.title.alternative Důležitost velikosti částic mezoporézní siliky pro stabilizaci amorfních léčiv - Případ Simvastatin cze
dc.type article eng
dc.description.abstract-translated Práce studuje roli mezoporézní siliky pro stabilizaci amorfního léčiva Simvastatin. Inhibice rekrystalizace je sledována metodami DSC a BDS. cze
dc.peerreviewed yes eng
dc.publicationstatus published version eng
dc.identifier.doi 10.3390/pharmaceutics12040384 eng
dc.relation.publisherversion https://www.mdpi.com/1999-4923/12/4/384 eng
dc.identifier.wos 000535575000089 eng
dc.identifier.scopus 2-s2.0-85083742684
dc.identifier.obd 39884914 eng


Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam

open access (CC BY 4.0) Kromě případů, kde je uvedeno jinak, licence tohoto záznamu je open access (CC BY 4.0)

Vyhledávání


Rozšířené hledání

Procházet

Můj účet